Company intelligence / Profile preview

Alimentiv Inc.

Ownership: Private
Employees: ~500
Development stage: Commercial

Overview

Alimentiv supports over 70% of all IBD compounds in development today, providing end-to-end clinical trial services with expertise in GI research[4]

Therapeutic areas: GastroenterologyMetabolic Disorders
Industry: Contract Research Organization

Partnerships

PhaseV (for machine learning-based GI clinical trials)Satisfai Health (for AI-powered scoring tool for ulcerative colitis)AcelaBio and PharmaNest (for AI to improve MASH trials)

Beyond the preview

Go deeper on Alimentiv Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alimentiv Inc..

Explore the full profile